The FDA's approval of a first-of-its-kind tau imaging agent for Alzheimer's is the kind of regulatory milestone that reshapes an entire sector. The companies in this group are right at the centre of that shift.
With more people than ever entering the age groups most at risk of cognitive decline, demand for specialised neurological diagnostics is set to rise significantly. This group of stocks sits directly in the path of that growing need.
Professional analysts handpicked each of these stocks in direct response to the TAUKLARIFY approval. From imaging equipment to drug development, these are the names that insiders are watching most closely right now.
This basket's total market capitalisation is 2,064,748.94 (as reported) and is dominated by a few large-cap constituents. That concentration produces a predominantly large-cap profile, implying lower relative volatility and market-tracking characteristics.
LNTH: $6.59B
LLY: $1.11T
BIIB: $31.00B
The FDA's approval of Lantheus Holdings' TAUKLARIFY — a radioactive PET imaging agent that visualises tau deposits in the brain — marks a turning point for Alzheimer's diagnostics. This theme captures the broader opportunity that follows: as advanced imaging becomes a routine part of cognitive evaluations, the entire diagnostics ecosystem stands to grow alongside it.
This group spans several parts of the healthcare sector, from radiopharmaceutical developers and medical imaging equipment makers to biomarker testing platforms and Alzheimer's drug manufacturers. Because these companies operate across a connected value chain, they can collectively benefit as demand for specialised neurological diagnostics increases. This is a growth-oriented theme within the broader healthcare space.
Each stock in this group was handpicked by professional analysts in direct response to the TAUKLARIFY regulatory milestone. They represent companies that are either developing the imaging agents, manufacturing the equipment that runs the scans, distributing the radioactive tracers, or creating the Alzheimer's treatments that depend on precise diagnostics — all key pieces of this expanding puzzle.
Lantheus Holdings recently secured FDA approval for a new radioactive imaging agent that helps detect tau pathology during Alzheimer's assessments. This regulatory success signals expanding opportunities for companies involved in specialized medical diagnostics and advanced radiopharmaceuticals.
Published on August 17
Get the full story on this Basket. Read our detailed article on its risks and potential.
Read Full Insight
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+116.49%
On average, analysts expect assets in this group to grow 116.49% over the next year.
8 of 12 assets in this group are rated Buy by professional analysts.
